Covid-19 roundup: US secures 100,000 doses of Eli Lilly's antibody cocktail; Merck's $356M supply deal on hold as FDA asks for more data
A couple weeks after racking up its third EUA for a Covid-19 treatment — this one for its antibody cocktail — Eli Lilly has struck a deal with the US government for at least 100,000 doses.
The US will pay $210 million for doses of bamlanivimab and etesevimab, which will be delivered through March 31, Lilly said in a statement. The deal builds on 1.45 million doses of bamlanivimab alone that the US has already purchased, more than 1 million of which have been delivered. Another 450,000 doses of the single antibody are also expected to arrive by March 31.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 107,000+ biopharma pros reading Endpoints daily — and it's free.